Search
Results: 98758
Alemtuzumab CARE-MS II 5-year follow-up
Alasdair J Coles, Jeffrey A Cohen, Edward J Fox, Gavin Giovannoni, Hans-Peter Hartung, Eva Havrdova, Sven Schippling, Krzysztof W Selmaj, Anthony Traboulsee, D Alastair S Compston, David H Margolin, Karthinathan Thangavelu, Madalina C Chirieac, Darlene Jody, Panos Xenopoulos, Richard J Hogan, Michael A Panzara, Douglas L Arnold, CARE-MS II and CAMMS03409 Investigators
Dec 11, 2017
OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and Rebif...
Infection risk with alemtuzumab decreases over time
Sibyl Wray, Eva Havrdova, David R Snydman, Douglas L Arnold, Jeffrey A Cohen, Alasdair J Coles, Hans-Peter Hartung, Krzysztof W Selmaj, Howard L Weiner, Nadia Daizadeh, David H Margolin, Madalina C Chirieac, D Alastair S Compston
Nov 22, 2018
BACKGROUND: Reduced MS disease activity with alemtuzumab versus subcutaneous interferon beta-1a (SC IFNB-1a) in core phase 2/3 studies was accompanied by increased incidence of infections that were mainly nonserious and...
Efficacy and safety of alemtuzumab over 6 years
Alasdair J Coles, Douglas L Arnold, Ann D Bass, Aaron L Boster, D Alastair S Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C Chirieac, Krzysztof W Selmaj
Jun 27, 2021
BACKGROUND: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous...
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
Blood Pressure Changes Following Antihypertensive Medication Reduction, by Drug Class and Dose Chosen for Withdrawal
James P. Sheppard, Mark Lown, Jenni Burt, Gary A. Ford, F. D. Richard Hobbs, Paul Little, Jonathan Mant, Rupert A. Payne, Richard J. McManus, On behalf of the OPTiMISE Investigators
May 04, 2021
Aims: Deprescribing of antihypertensive drugs is recommended for some older patients with polypharmacy, but there is little evidence to inform which drug (or dose) should be withdrawn. This study used data from the OPTiMISE...
Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016
Rachel Charlton, Christine Damase-Michel, Caroline Hurault-Delarue, Rosa Gini, Maria Loane, Anna Pierini, Aurora Puccini, Amanda Neville, Julia Snowball, Joan Morris, on behalf of the EUROmediSAFE Consortium
Nov 01, 2019
Objectives
In November 2014, the CMDh (a regulatory body representing EU Member States) advised doctors not to prescribe sodium valproate for epilepsy or bipolar disorder in preg nant women, in women who can become pregnant...
In November 2014, the CMDh (a regulatory body representing EU Member States) advised doctors not to prescribe sodium valproate for epilepsy or bipolar disorder in preg nant women, in women who can become pregnant...
Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016
Rachel Charlton, Christine Damase-Michel, Caroline Hurault-Delarue, Rosa Gini, Maria Loane, Anna Pierini, Aurora Puccini, Amanda Neville, Julia Snowball, Joan Morris, on behalf of the EUROmediSAFE Consortium
Nov 01, 2019
Objectives
In November 2014, the CMDh (a regulatory body representing EU Member States) advised doctors not to prescribe sodium valproate for epilepsy or bipolar disorder in preg nant women, in women who can become pregnant...
In November 2014, the CMDh (a regulatory body representing EU Member States) advised doctors not to prescribe sodium valproate for epilepsy or bipolar disorder in preg nant women, in women who can become pregnant...
Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care
Peter Le Roux, David K Menon, Giuseppe Citerio, Paul Vespa, Mary Kay Bader, Gretchen M Brophy, Michael N Diringer, Nino Stocchetti, Walter Videtta, Rocco Armonda, Neeraj Badjatia, Julian Böesel, Randall Chesnut, Sherry Chou, Jan Claassen, Marek Czosnyka, Michael De Georgia, Anthony Figaji, Jennifer Fugate, Raimund Helbok, David Horowitz, Peter Hutchinson, Monisha Kumar, Molly McNett, Chad Miller, Andrew Naidech, Mauro Oddo, DaiWai Olson, Kristine O'Phelan, J Javier Provencio, Corinna Puppo, Richard Riker, Claudia Robertson, Michael Schmidt, Fabio Taccone, Neurocritical Care Society, European Society of Intensive Care Medicine
Jan 09, 2019
Neurocritical care depends, in part, on careful patient monitoring but as yet there are little data on what processes are the most important to monitor, how these should be monitored, and whether monitoring these processes is...
Factorial Structure and Validity of Depression (PHQ-9) and Anxiety (GAD-7) Scales after Traumatic Brain Injury
Ali Teymoori, Anastasia Gorbunova, Fardzadeh E. Haghish, Ruben Real, Marina Zeldovich, Yi-Jhen Wu, Suzanne Polinder, Thomas Asendorf, David Menon, CENTER-TBI Investigators and Participants CENTER-TBI Investigators and Participants, Nicole v. Steinbüchel
Mar 25, 2020
Background: The dimensionality of depression and anxiety instruments have recently been a source of controversy. Objectives and Design: In a European-wide sample of patients after Traumatic Brain Injury (TBI), we aim to examine...
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
G Giovannoni, JA Cohen, AJ Coles, H-P Hartung, E Havrdova, KW Selmaj, DH Margolin, SL Lake, SM Kaup, MA Panzara, DAS Compston, CARE-MS II Investigators
Jan 11, 2017
Adjuvants Immunologic Alemtuzumab Analysis of Variance Antibodies Monoclonal Humanized Antineoplastic Agents Disability Evaluation Disabled Persons Female Humans Interferon-beta Kaplan-Meier Estimate Longitudinal Studies Male Multiple Sclerosis Relapsing-Remitting Severity of Illness Index Treatment Outcome
Comment on Herring et al. The Use of "Retardation" in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044.
This commentary is written in response to the recent article from Herring et al., discussing the eradication of the offensive term "retardation" from gene nomenclature. We discuss the work of the HUGO (Human Genome Organisation)...
Variation in Structure and Process of Care in Traumatic Brain Injury
Maryse C Cnossen, Suzanne Polinder, Hester F Lingsma, Andrew IR Maas, David Menon, Ewout W Steyerberg, CENTER-TBI Investigators and Participants
Jun 19, 2018
INTRODUCTION: The strength of evidence underpinning care and treatment recommendations in traumatic brain injury (TBI) is low. Comparative effectiveness research (CER) has been proposed as a framework to provide evidence for...
W451-002B-06 - Division of Student Life: Office of Health and Counseling Services: Office of Accessibility- Correspondence and Memoranda
Division of Student Life, Health and Counseling Services, Office of, Disability Services, Office of, Accessibility, Office of, Testing Program
Jan 01, 0001
Published by: Winthrop University
Undergraduate Scholarship in the College of Arts and Sciences 2003 Book of Abstracts
On behalf of the faculty, staff, and students in the College of Arts and Sciences, I want to thank you for your interest in this collection of abstracts of undergraduate research for 2003. This collection is the first we have...
Published by: Winthrop University
W404-010J-01 - Office of the Vice President for Academic Affairs: Office of Sponsored Programs and Research (SPAR): Correspondence and Memoranda
Office of Vice President for Academic Affairs, Sponsored Programs and Research, Office of, Grants and Sponsored Research Development, Office of
Jan 01, 0001
Published by: Winthrop University
The impact of a needs‐based model of care on accessibility and quality of care within children's mental health services
Abstract: Background: The i‐THRIVE Programme is a needs‐based model of care, based on the THRIVE Framework, that is being implemented across the United Kingdom with the aim of improving outcomes for children and young people's...
Modifiable pathways in Alzheimer's disease
Susanna C Larsson, Matthew Traylor, Rainer Malik, Martin Dichgans, Stephen Burgess, Hugh S Markus, on behalf of the International Genomics of Alzheimer’s Project CoSTREAM Consortium
Mar 07, 2018
OBJECTIVE: To determine which potentially modifiable risk factors, including socioeconomic, lifestyle/dietary, cardiometabolic, and inflammatory factors, are associated with Alzheimer's disease. DESIGN: Mendelian randomisation...
CONSORT-SPI 2018 Explanation and Elaboration
Sean Grant, Evan Mayo-Wilson, Paul Montgomery, Geraldine Macdonald, Susan Michie, Sally Hopewell, David Moher, on behalf of the CONSORT-SPI Group
Jan 08, 2019
BACKGROUND: The CONSORT (Consolidated Standards of Reporting Trials) Statement was developed to help biomedical researchers report randomised controlled trials (RCTs) transparently. We have developed an extension to the CONSORT...
CONSORT randomised controlled trial Reporting guideline reporting standards Transparency Behavior Therapy Checklist Consensus Data Accuracy Delphi Technique Endpoint Determination Humans Outcome Assessment Health Care Randomized Controlled Trials as Topic Research Design Social Environment Treatment Outcome
Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data
Lina Keutzer, Huifang You, Ali Farnoud, Joakim Nyberg, Sebastian G Wicha, Gareth Maher-Edwards, Georgios Vlasakakis, Gita Khalili Moghaddam, Elin M Svensson, Michael P Menden, Ulrika SH Simonsson, On Behalf Of The Unite Tb Consortium
Jul 23, 2022
Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development to characterize pharmacokinetics (PK) and pharmacodynamics (PD). Pharmacokinetic/pharmacodynamic (PKPD) analysis using PM provides mechanistic...
|
|< |
< |
1 |